Adjuvant Docetaxel for Node-Positive Breast Cancer
To the Editor: The study by Martin et al. (June 2 issue) 1 raises concern about the high rates of febrile neutropenia among patients receiving a regimen of docetaxel plus doxorubicin and cyclophosphamide (TAC). Moreover, it is not clear that the right comparator is a regimen of fluorouracil plus dox...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2005-09, Vol.353 (9), p.954-955 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 955 |
|---|---|
| container_issue | 9 |
| container_start_page | 954 |
| container_title | The New England journal of medicine |
| container_volume | 353 |
| creator | Ahluwalia, Manmeet S Daw, Hamed A |
| description | To the Editor:
The study by Martin et al. (June 2 issue)
1
raises concern about the high rates of febrile neutropenia among patients receiving a regimen of docetaxel plus doxorubicin and cyclophosphamide (TAC). Moreover, it is not clear that the right comparator is a regimen of fluorouracil plus doxorubicin and cyclophosphamide (FAC). Dose-dense regimens have been shown to be effective and less toxic.
2
A recent study was prematurely terminated because of an unacceptable rate of life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel.
3
We think that docetaxel-based adjuvant chemotherapy cannot be advocated as a standard approach in the management of . . . |
| doi_str_mv | 10.1056/NEJMc051802 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1056_NEJMc051802</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16135845</sourcerecordid><originalsourceid>FETCH-LOGICAL-c383t-5f047451a1daaf9e1dab9537828fc58f1e065b30b0ec22a52ab61aa0162a67e03</originalsourceid><addsrcrecordid>eNptj0tLw0AURgdRbK2u3EvApUTvPDNZ1lhf1OpC1-FmcgdamqbMpEX_vZEWdOG3-TaHA4excw7XHLS5mU2eXxxobkEcsCHXUqZKgTlkQwBhU5XlcsBOYlxAP67yYzbghkttlR4yMa4Xmy2uuuSuddThJy0T34Zk1taUvrVx3s23lNwGwtglBa4chVN25HEZ6Wz_I_ZxP3kvHtPp68NTMZ6mTlrZpdqDypTmyGtEn1N_Va5lZoX1TlvPCYyuJFRATgjUAivDEYEbgSYjkCN2tfO60MYYyJfrMG8wfJUcyp_y8k95T1_s6PWmaqj-ZfepPXC5A5omlitaNP9qvgFgC1zX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Adjuvant Docetaxel for Node-Positive Breast Cancer</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Ahluwalia, Manmeet S ; Daw, Hamed A</creator><creatorcontrib>Ahluwalia, Manmeet S ; Daw, Hamed A</creatorcontrib><description>To the Editor:
The study by Martin et al. (June 2 issue)
1
raises concern about the high rates of febrile neutropenia among patients receiving a regimen of docetaxel plus doxorubicin and cyclophosphamide (TAC). Moreover, it is not clear that the right comparator is a regimen of fluorouracil plus doxorubicin and cyclophosphamide (FAC). Dose-dense regimens have been shown to be effective and less toxic.
2
A recent study was prematurely terminated because of an unacceptable rate of life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel.
3
We think that docetaxel-based adjuvant chemotherapy cannot be advocated as a standard approach in the management of . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMc051802</identifier><identifier>PMID: 16135845</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Breast Neoplasms - drug therapy ; Breast Neoplasms - mortality ; Chemotherapy, Adjuvant - adverse effects ; Cyclophosphamide - administration & dosage ; Cyclophosphamide - adverse effects ; Dose-Response Relationship, Drug ; Doxorubicin - administration & dosage ; Doxorubicin - adverse effects ; Fluorouracil - administration & dosage ; Fluorouracil - adverse effects ; Humans ; Lymphatic Metastasis ; Neutropenia - chemically induced ; Sepsis - chemically induced ; Taxoids - administration & dosage ; Taxoids - adverse effects</subject><ispartof>The New England journal of medicine, 2005-09, Vol.353 (9), p.954-955</ispartof><rights>Copyright © 2005 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c383t-5f047451a1daaf9e1dab9537828fc58f1e065b30b0ec22a52ab61aa0162a67e03</citedby><cites>FETCH-LOGICAL-c383t-5f047451a1daaf9e1dab9537828fc58f1e065b30b0ec22a52ab61aa0162a67e03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMc051802$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMc051802$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2745,2746,26082,27903,27904,52360,54042</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16135845$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ahluwalia, Manmeet S</creatorcontrib><creatorcontrib>Daw, Hamed A</creatorcontrib><title>Adjuvant Docetaxel for Node-Positive Breast Cancer</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>To the Editor:
The study by Martin et al. (June 2 issue)
1
raises concern about the high rates of febrile neutropenia among patients receiving a regimen of docetaxel plus doxorubicin and cyclophosphamide (TAC). Moreover, it is not clear that the right comparator is a regimen of fluorouracil plus doxorubicin and cyclophosphamide (FAC). Dose-dense regimens have been shown to be effective and less toxic.
2
A recent study was prematurely terminated because of an unacceptable rate of life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel.
3
We think that docetaxel-based adjuvant chemotherapy cannot be advocated as a standard approach in the management of . . .</description><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - mortality</subject><subject>Chemotherapy, Adjuvant - adverse effects</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Cyclophosphamide - adverse effects</subject><subject>Dose-Response Relationship, Drug</subject><subject>Doxorubicin - administration & dosage</subject><subject>Doxorubicin - adverse effects</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - adverse effects</subject><subject>Humans</subject><subject>Lymphatic Metastasis</subject><subject>Neutropenia - chemically induced</subject><subject>Sepsis - chemically induced</subject><subject>Taxoids - administration & dosage</subject><subject>Taxoids - adverse effects</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptj0tLw0AURgdRbK2u3EvApUTvPDNZ1lhf1OpC1-FmcgdamqbMpEX_vZEWdOG3-TaHA4excw7XHLS5mU2eXxxobkEcsCHXUqZKgTlkQwBhU5XlcsBOYlxAP67yYzbghkttlR4yMa4Xmy2uuuSuddThJy0T34Zk1taUvrVx3s23lNwGwtglBa4chVN25HEZ6Wz_I_ZxP3kvHtPp68NTMZ6mTlrZpdqDypTmyGtEn1N_Va5lZoX1TlvPCYyuJFRATgjUAivDEYEbgSYjkCN2tfO60MYYyJfrMG8wfJUcyp_y8k95T1_s6PWmaqj-ZfepPXC5A5omlitaNP9qvgFgC1zX</recordid><startdate>20050901</startdate><enddate>20050901</enddate><creator>Ahluwalia, Manmeet S</creator><creator>Daw, Hamed A</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20050901</creationdate><title>Adjuvant Docetaxel for Node-Positive Breast Cancer</title><author>Ahluwalia, Manmeet S ; Daw, Hamed A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c383t-5f047451a1daaf9e1dab9537828fc58f1e065b30b0ec22a52ab61aa0162a67e03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - mortality</topic><topic>Chemotherapy, Adjuvant - adverse effects</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Cyclophosphamide - adverse effects</topic><topic>Dose-Response Relationship, Drug</topic><topic>Doxorubicin - administration & dosage</topic><topic>Doxorubicin - adverse effects</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - adverse effects</topic><topic>Humans</topic><topic>Lymphatic Metastasis</topic><topic>Neutropenia - chemically induced</topic><topic>Sepsis - chemically induced</topic><topic>Taxoids - administration & dosage</topic><topic>Taxoids - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ahluwalia, Manmeet S</creatorcontrib><creatorcontrib>Daw, Hamed A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ahluwalia, Manmeet S</au><au>Daw, Hamed A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adjuvant Docetaxel for Node-Positive Breast Cancer</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2005-09-01</date><risdate>2005</risdate><volume>353</volume><issue>9</issue><spage>954</spage><epage>955</epage><pages>954-955</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>To the Editor:
The study by Martin et al. (June 2 issue)
1
raises concern about the high rates of febrile neutropenia among patients receiving a regimen of docetaxel plus doxorubicin and cyclophosphamide (TAC). Moreover, it is not clear that the right comparator is a regimen of fluorouracil plus doxorubicin and cyclophosphamide (FAC). Dose-dense regimens have been shown to be effective and less toxic.
2
A recent study was prematurely terminated because of an unacceptable rate of life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel.
3
We think that docetaxel-based adjuvant chemotherapy cannot be advocated as a standard approach in the management of . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>16135845</pmid><doi>10.1056/NEJMc051802</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2005-09, Vol.353 (9), p.954-955 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_crossref_primary_10_1056_NEJMc051802 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - mortality Chemotherapy, Adjuvant - adverse effects Cyclophosphamide - administration & dosage Cyclophosphamide - adverse effects Dose-Response Relationship, Drug Doxorubicin - administration & dosage Doxorubicin - adverse effects Fluorouracil - administration & dosage Fluorouracil - adverse effects Humans Lymphatic Metastasis Neutropenia - chemically induced Sepsis - chemically induced Taxoids - administration & dosage Taxoids - adverse effects |
| title | Adjuvant Docetaxel for Node-Positive Breast Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T14%3A13%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adjuvant%20Docetaxel%20for%20Node-Positive%20Breast%20Cancer&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Ahluwalia,%20Manmeet%20S&rft.date=2005-09-01&rft.volume=353&rft.issue=9&rft.spage=954&rft.epage=955&rft.pages=954-955&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMc051802&rft_dat=%3Cpubmed_cross%3E16135845%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/16135845&rfr_iscdi=true |